CANCER CENTER SUPPORT GRANT

$11,526,509P30FY2007CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications, trials & patents

Paper 39713466 Paper 39666914 Paper 39605676 Paper 39593217 Paper 39536083 Paper 39532885 Paper 39484503 Paper 39389170 Paper 39322760 Paper 39168126 Paper 39160372 Paper 39107288 Paper 39042477 Paper 39025073 Paper 39024561 Paper 38996877 Paper 38992034 Paper 38979326 Paper 38979245 Paper 38942046 Paper 38924531 Paper 38889153 Paper 38861327 Paper 38815709 Trial NCT03029325 Trial NCT02627430 Trial NCT02142803 Trial NCT02097225 Trial NCT02079740 Trial NCT01940809 Trial NCT01835184 Trial NCT01822509 Trial NCT01575522 Trial NCT01434316 Trial NCT01307631 Trial NCT01283035 Trial NCT01116648 Trial NCT01026324 Trial NCT00956163 Trial NCT00888134 Trial NCT00662506 Trial NCT00622401 Trial NCT00458978 Trial NCT00458549 Trial NCT00429910 Trial NCT00400946 Trial NCT00376480 Trial NCT00357500 Trial NCT00301093 Trial NCT00126672 Trial NCT00101075 Trial NCT00098865 Trial NCT00098514 Trial NCT00096291 Trial NCT00095927 Trial NCT00095901 Trial NCT00095875 Trial NCT00095836 Trial NCT00090857 Trial NCT00084838 Trial NCT00083031 Trial NCT00079326 Trial NCT00072436 Trial NCT00069940 Trial NCT00053976 Trial NCT00052611 Trial NCT00047294 Trial NCT00047281 Trial NCT00020670 Trial NCT00020605 Trial NCT00007917 Trial NCT00006107 Trial NCT00005988 Trial NCT00005096 Trial NCT00004180 Trial NCT00004163 Trial NCT00004070 Trial NCT00003761 Trial NCT00003744 Trial NCT00003657 Trial NCT00003200 Trial NCT00003058 Trial NCT00003045 Patent 9512485 Patent 7786269 Patent 7396678 Patent 7229755 Patent 7048929 Patent 6908617 Patent 6479284 Patent 6479281 Patent 5861424 Patent 5670530 Patent 5618831 Patent 5502214 Patent 5360803 Patent 4625014 Patent 4618492 Patent 4542225 Patent 4035566

Abstract

DESCRIPTION (provided by applicant): Dana Farber/Harvard Cancer Center (DF/HCC) is an inter-institutional research enterprise that unites the major clinical, population, and basic cancer research efforts of the Harvard medical and public health community. It was founded in 1998 through a formal agreement of the Dana-Farber Cancer Institute, the Harvard Medical School and Harvard School of Medicine and Public Health, and the Beth Israel Deaconess, Brigham and Women's, Children's, and Massachusetts General Hospitals. By agreement, this will be the only NCI-designated Cancer Center application from these institutions. The DF/HCC links the efforts of a large cadre of cancer scientists - currently more than 800 members with NCI grants amounting to more than $200 million in total costs-in an interlocking organizational structure designed to promote research advances that are aimed at lowering the burden of cancer. In the aggregate, Center members have extensive experience and well-recognized expertise in the three major cancer research disciplines: basic, clinical, and population science. The research of the Center is carried out in 17 disease site- and discipline-based Research Programs that cross both institutional and scientific boundaries. In addition, the Center supports 19 Core Facilities that make shared resources, dedicated to enhancing scientific efficiency, available to all Center members. The primary goal of the Center is to promote collaborative interactions that will lead to new approaches to cancer prevention, diagnosis, and treatment.

View original record on NIH RePORTER →